Results 31 to 40 of about 1,083,500 (167)

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy [PDF]

open access: yesEur Psychiatry
Introduction One of the main mechanisms of action of LSD in psychedelic-assisted psychotherapy (PAP) is the activation of 5HT2A receptors. This triggers a cascade of neurochemical processes with the release of neurotransmitters and neurohormonal substances.
Cazorla L   +8 more
europepmc   +3 more sources

Psychedelic assisted psychotherapy (2020–2025): a scoping review of clinical evidence, mechanisms, safety, and ethics [PDF]

open access: yesFrontiers in Psychology
BackgroundClinical research on psychedelic-assisted therapy (PAT) has expanded substantially in recent years, particularly for post-traumatic stress disorder (PTSD) and depressive disorders.
Nasiru Mohammed Abdullahi   +23 more
doaj   +2 more sources

Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers. [PDF]

open access: yesAust N Z J Psychiatry
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression.
Nadeem Z   +4 more
europepmc   +2 more sources

Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems [PDF]

open access: yesFrontiers in Psychiatry, 2021
Elena Argento   +6 more
doaj   +2 more sources

Psychedelic assisted psychotherapy: a person-centred approach

open access: yes
This thesis explores the role of the therapist in Psychedelic-Assisted Psychotherapy (PAT) through the lens of Carl Rogers Person-Centred Therapy (PCT).
Browne, Niamh
core   +3 more sources

Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review [PDF]

open access: yesFrontiers in Psychiatry
IntroductionPsychedelic-assisted therapy (PAT) is an emerging complex intervention for psychiatric and existential conditions (i.e., forms of distress related to meaning, mortality, and identity, such as that arising in life-threatening illness); however,
Maria Laura Mele   +3 more
doaj   +2 more sources

Conceptual analysis of mechanisms and methods in psychedelic clinical trial design: a narrative review [PDF]

open access: yesTherapeutic Advances in Psychopharmacology
Clinical trials with psychedelics face several challenges that are not present to such a degree with other pharmacotherapeutics. Psychedelic therapies often include a significant therapeutic container, including preparatory and integrative psychotherapy,
Martin Krsak   +4 more
doaj   +2 more sources

Extrapharmacological Safety Topics in Psychedelic-Assisted Psychotherapy

open access: yesJAMA Psychiatry, 2023
This Viewpoint proposes methods for optimizing patient and therapist safety during psychedelic-assisted psychotherapy.
Calder, Abigail, Hasler, Gregor
openaire   +3 more sources

Psychedelic-assisted psychotherapy, patient vulnerability and abuses of power

open access: yesAustralian & New Zealand Journal of Psychiatry, 2023
Recent high-profile findings supporting the possible efficacy of psychedelic-assisted psychotherapy (Psy-AP) for indications including treatment-resistant depression and post-traumatic stress disorder make it increasingly likely that these treatments will become more widely available.
Sally Meikle   +2 more
openaire   +2 more sources

Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default

open access: yesFrontiers in Psychology, 2022
The acute subjective effects of psychedelics are responsive to users’ expectations and surroundings (i.e., “set and setting”). Accordingly, a great deal of thought has gone into designing the psychosocial context of psychedelic administration in clinical
David B. Yaden   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy